UY32424A - Comprimidos conteniendo elivitegravir para tratamiento de infecciones virales - Google Patents

Comprimidos conteniendo elivitegravir para tratamiento de infecciones virales

Info

Publication number: UY32424A
Authority: UY; Uruguay
Prior art keywords: elivitegravir; treatment; viral infections; tablets containing; formula
Prior art date: 2009-02-06

Application number

UY0001032424A

Other languages

English (en)

Spanish (es)

Inventor

Oliyai Reza

Mark M Menning

Joanna M Koziara

Original Assignee

Gilead Science Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-02-06

Filing date

2010-02-08

Publication date

2010-09-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41722740&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY32424(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-02-08 Application filed by Gilead Science Inc filed Critical Gilead Science Inc

2010-09-30 Publication of UY32424A publication Critical patent/UY32424A/es

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

UY0001032424A 2009-02-06 2010-02-08 Comprimidos conteniendo elivitegravir para tratamiento de infecciones virales UY32424A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US15065209P	2009-02-06	2009-02-06
US15065509P	2009-02-06	2009-02-06

Publications (1)

Publication Number	Publication Date
UY32424A true UY32424A (es)	2010-09-30

Family

ID=41722740

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UY0001032424A UY32424A (es)	2009-02-06	2010-02-08	Comprimidos conteniendo elivitegravir para tratamiento de infecciones virales

Country Status (30)

Country	Link
US (2)	US20100285122A1 (pl)
EP (1)	EP2393485B1 (pl)
JP (2)	JP5611242B2 (pl)
KR (2)	KR101645759B1 (pl)
CN (1)	CN102307573B (pl)
AP (1)	AP3250A (pl)
AR (1)	AR075369A1 (pl)
AU (1)	AU2010210598B2 (pl)
BR (1)	BRPI1008664A2 (pl)
CA (1)	CA2750521A1 (pl)
CL (1)	CL2011001885A1 (pl)
CY (1)	CY1116852T1 (pl)
DK (1)	DK2393485T3 (pl)
EA (2)	EA021313B1 (pl)
EC (1)	ECSP11011307A (pl)
ES (1)	ES2548886T3 (pl)
HR (1)	HRP20151009T1 (pl)
HU (1)	HUE025822T2 (pl)
IL (1)	IL214227A (pl)
MX (1)	MX2011008289A (pl)
NZ (1)	NZ594214A (pl)
PE (1)	PE20110994A1 (pl)
PL (1)	PL2393485T3 (pl)
PT (1)	PT2393485E (pl)
SG (3)	SG173544A1 (pl)
SI (1)	SI2393485T1 (pl)
SM (1)	SMT201500266B (pl)
TW (1)	TWI444367B (pl)
UY (1)	UY32424A (pl)
WO (1)	WO2010091197A2 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI2049506T2 (sl)	2006-07-07	2024-07-31	Gilead Sciences, Inc.	Modulatorji farmakokinetičnih lastnosti terapevtikov
EP4403221A3 (en) *	2007-02-23	2024-10-09	Gilead Sciences, Inc.	Modulators of pharmacokinetic properties of therapeutics
CN103479584A (zh)	2008-05-02	2014-01-01	吉里德科学公司	固体载体颗粒在改善药物制剂加工性中的应用
TWI556840B (zh)	2010-11-19	2016-11-11	吉李德科學股份有限公司	治療用組成物
WO2012072580A1 (en) *	2010-11-29	2012-06-07	Formac Pharmaceuticals N.V.	Compressed formulations of ordered mesoporous silicas
SI2729130T1 (en) *	2011-07-07	2018-03-30	Janssen Sciences Ireland Uc	Combined formulations of darunavir
CN110343135A (zh)	2011-08-16	2019-10-18	吉利德科学公司	替诺福韦艾拉酚胺(tenofovir alafenamide)半反丁烯二酸盐
WO2013115916A1 (en) *	2012-02-03	2013-08-08	Gilead Sciences, Inc.	Combination therapy comprising gs-7340 and cobicistat for use in the treatment of viral infections
MD20140091A2 (ro) *	2012-02-03	2015-01-31	Gilead Sciences, Inc.	Terapie combinată cuprinzând hemifumarat tenofovir alafenamidă şi cobicistat pentru utilizare în tratamentul infecţiilor virale
JP2015508822A (ja) *	2012-03-01	2015-03-23	ギリアードサイエンシーズ，インコーポレイテッド	噴霧乾燥製剤
CN103830192A (zh) *	2012-11-27	2014-06-04	安徽贝克生物制药有限公司	一种可粉末直接压片的富马酸替诺福韦二吡呋酯片剂及制备方法
CA2893843C (en)	2012-12-21	2018-09-04	Gilead Sciences, Inc.	Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EA201792592A1 (ru)	2015-06-30	2018-06-29	Джилид Сайэнс, Инк.	Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
SI3346995T1 (sl)	2015-11-09	2019-11-29	Gilead Sciences Inc	Terapevtski sestavek za zdravljenje virusa človeške imunske pomanjkljivosti
WO2017134089A1 (en)	2016-02-02	2017-08-10	Sandoz Ag	Crystalline forms of tenofovir alafenamide monofumarate
WO2022034232A1 (en) *	2020-08-13	2022-02-17	Alfred E. Tiefenbacher (Gmbh & Co. Kg)	Gastro-resistant high-strength formulation containing posaconazole

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA923641B (en)	1991-05-21	1993-02-24	Iaf Biochem Int	Processes for the diastereoselective synthesis of nucleosides
US5922695A (en)	1996-07-26	1999-07-13	Gilead Sciences, Inc.	Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
DE10153078A1 (de) *	2001-10-30	2003-05-22	Degussa	Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen
JP3567162B1 (ja) *	2002-11-20	2004-09-22	日本たばこ産業株式会社	４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
CN100375742C (zh) *	2002-11-20	2008-03-19	日本烟草产业株式会社	4-氧代喹啉化合物及其用途
WO2004046115A1 (ja)	2002-11-20	2004-06-03	Japan Tobacco Inc.	４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
EA015145B1 (ru)	2003-01-14	2011-06-30	Джилид Сайэнс, Инк.	Фармацевтическая композиция и пероральная фармацевтическая дозированная форма (варианты), проявляющие активность в отношении вич-инфекций, лечебный набор и таблетка и способ лечения или предотвращения симптомов или эффектов вич-инфекции
MY134672A (en)	2004-05-20	2007-12-31	Japan Tobacco Inc	Stable crystal of 4-oxoquinoline compound
TWI375560B (en)	2005-06-13	2012-11-01	Gilead Sciences Inc	Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh)	2005-06-13	2015-02-01	Bristol Myers Squibb & Gilead Sciences Llc	單一式藥學劑量型
US20080317852A1 (en) *	2005-12-14	2008-12-25	Amar Lulla	Pharmaceutical Combination
SI2049506T2 (sl)	2006-07-07	2024-07-31	Gilead Sciences, Inc.	Modulatorji farmakokinetičnih lastnosti terapevtikov
EP4403221A3 (en)	2007-02-23	2024-10-09	Gilead Sciences, Inc.	Modulators of pharmacokinetic properties of therapeutics

2010
- 2010-02-04 CN CN2010800066460A patent/CN102307573B/zh not_active Expired - Fee Related
- 2010-02-04 SI SI201031019T patent/SI2393485T1/sl unknown
- 2010-02-04 EP EP10703766.5A patent/EP2393485B1/en not_active Revoked
- 2010-02-04 EA EA201190125A patent/EA021313B1/ru not_active IP Right Cessation
- 2010-02-04 SG SG2011056306A patent/SG173544A1/en unknown
- 2010-02-04 SG SG10201706215UA patent/SG10201706215UA/en unknown
- 2010-02-04 DK DK10703766.5T patent/DK2393485T3/en active
- 2010-02-04 KR KR1020117020652A patent/KR101645759B1/ko not_active Expired - Fee Related
- 2010-02-04 JP JP2011549268A patent/JP5611242B2/ja not_active Expired - Fee Related
- 2010-02-04 WO PCT/US2010/023226 patent/WO2010091197A2/en not_active Ceased
- 2010-02-04 ES ES10703766.5T patent/ES2548886T3/es active Active
- 2010-02-04 MX MX2011008289A patent/MX2011008289A/es active IP Right Grant
- 2010-02-04 SG SG2014007744A patent/SG2014007744A/en unknown
- 2010-02-04 PE PE2011001449A patent/PE20110994A1/es active IP Right Grant
- 2010-02-04 BR BRPI1008664A patent/BRPI1008664A2/pt not_active Application Discontinuation
- 2010-02-04 KR KR1020167020504A patent/KR101738325B1/ko not_active Expired - Fee Related
- 2010-02-04 US US12/700,608 patent/US20100285122A1/en not_active Abandoned
- 2010-02-04 HU HUE10703766A patent/HUE025822T2/en unknown
- 2010-02-04 EA EA201491658A patent/EA030123B1/ru not_active IP Right Cessation
- 2010-02-04 AP AP2011005857A patent/AP3250A/xx active
- 2010-02-04 AU AU2010210598A patent/AU2010210598B2/en not_active Ceased
- 2010-02-04 NZ NZ594214A patent/NZ594214A/xx not_active IP Right Cessation
- 2010-02-04 PL PL10703766T patent/PL2393485T3/pl unknown
- 2010-02-04 CA CA2750521A patent/CA2750521A1/en not_active Abandoned
- 2010-02-04 PT PT107037665T patent/PT2393485E/pt unknown
- 2010-02-04 HR HRP20151009TT patent/HRP20151009T1/hr unknown
- 2010-02-05 AR ARP100100328A patent/AR075369A1/es unknown
- 2010-02-06 TW TW099103651A patent/TWI444367B/zh not_active IP Right Cessation
- 2010-02-08 UY UY0001032424A patent/UY32424A/es not_active Application Discontinuation
2011
- 2011-07-21 IL IL214227A patent/IL214227A/en not_active IP Right Cessation
- 2011-08-05 CL CL2011001885A patent/CL2011001885A1/es unknown
- 2011-09-06 EC EC2011011307A patent/ECSP11011307A/es unknown
2014
- 2014-09-02 JP JP2014178005A patent/JP5911927B2/ja active Active
2015
- 2015-02-06 US US14/616,563 patent/US20150150810A1/en not_active Abandoned
- 2015-10-26 CY CY20151100953T patent/CY1116852T1/el unknown
- 2015-10-28 SM SM201500266T patent/SMT201500266B/it unknown

Also Published As

Publication number	Publication date
ES2548886T3 (es)	2015-10-21
CY1116852T1 (el)	2017-04-05
IL214227A0 (en)	2011-09-27
SMT201500266B (it)	2016-01-08
EA021313B1 (ru)	2015-05-29
EP2393485B1 (en)	2015-07-29
CA2750521A1 (en)	2010-08-12
HK1164737A1 (en)	2012-09-28
AU2010210598B2 (en)	2015-03-05
TW201040142A (en)	2010-11-16
BRPI1008664A2 (pt)	2016-03-08
JP5611242B2 (ja)	2014-10-22
US20100285122A1 (en)	2010-11-11
EA201190125A1 (ru)	2012-01-30
SG173544A1 (en)	2011-09-29
AP2011005857A0 (en)	2011-10-31
NZ594214A (en)	2013-05-31
EA030123B1 (ru)	2018-06-29
KR101738325B1 (ko)	2017-05-19
AU2010210598A1 (en)	2011-08-25
US20150150810A1 (en)	2015-06-04
JP2014221845A (ja)	2014-11-27
KR20160093100A (ko)	2016-08-05
KR101645759B1 (ko)	2016-08-04
AP3250A (en)	2015-05-31
CN102307573A (zh)	2012-01-04
CL2011001885A1 (es)	2012-05-25
DK2393485T3 (en)	2015-10-26
EP2393485A2 (en)	2011-12-14
WO2010091197A2 (en)	2010-08-12
HRP20151009T1 (hr)	2015-10-23
PT2393485E (pt)	2015-10-23
PL2393485T3 (pl)	2015-12-31
CN102307573B (zh)	2013-09-11
KR20110122729A (ko)	2011-11-10
AR075369A1 (es)	2011-03-30
SG10201706215UA (en)	2017-08-30
TWI444367B (zh)	2014-07-11
SG2014007744A (en)	2014-05-29
PE20110994A1 (es)	2012-01-24
SI2393485T1 (sl)	2015-10-30
EA201491658A1 (ru)	2015-05-29
IL214227A (en)	2017-01-31
ECSP11011307A (es)	2011-10-31
JP2012517432A (ja)	2012-08-02
HUE025822T2 (en)	2016-04-28
JP5911927B2 (ja)	2016-04-27
MX2011008289A (es)	2011-09-15
WO2010091197A3 (en)	2011-06-03

Legal Events

Date	Code	Title	Description
2020-12-23	RDES	Application refused	Effective date: 20201223

Publication	Publication Date	Title
ECSP11011307A (es)	2011-10-31	Comprimidos para terapia de combinacion
CO6511251A2 (es)	2012-08-31	Compuestos quimicos
MX2012006233A (es)	2012-07-03	Nuevos compuestos de espiropiperidina.
CL2008000403A1 (es)	2008-08-18	Compuestos derivados de pentafluorotiobenzamido-acetonitrilo; composicion farmaceutica; y uso para tratar una infestacion por parasitos.
CL2013002417A1 (es)	2013-12-13	Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
ECSP12011799A (es)	2012-07-31	Compuestos de espiropiperidina y uso farmacéutico de los mismos
EA201200550A1 (ru)	2012-12-28	Фармацевтические композиции, включающие bi-1356 и метформин
MX2007009162A (es)	2007-10-23	Formas de dosis rsistente al alcohol.
CL2012001959A1 (es)	2012-12-07	Compuestos derivados del acido tiofeno-2-carboxilico, inhibidores de virus flaviviridae; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral por flaviviridae.
CL2015002698A1 (es)	2016-08-19	Nuevos compuestos y composiciones para la inhibicion de fasn
CL2011000558A1 (es)	2011-07-15	Formas cristalinas de un compuesto derivado de 2-tiazolil-4-quinolinil-oxi; sal de sodio del compuesto, composicion farmaceutica que comprende la sal de sodio, util para tratar una infeccion por el virus de la hepatitis c.
CL2014000468A1 (es)	2014-10-17	Compuestos derivados del acido 2-oxo-6-(fenil/heteroaril)l-1,2-dihidropiridin-3-carboxilico; composicion farmaceutica; combinacion; y su uso para el alivio de una infeccion bacteriana.
MA33803B1 (fr)	2012-12-03	Inhibiteur de bromodomaine de benzodiazépine
CR20110432A (es)	2011-10-24	Pirimidinas fusionadas
HN2012000023A (es)	2014-08-18	Compuestos y composiciones para el tratamiento de enfermedades parasitarias
EA201270590A1 (ru)	2012-09-28	Ингибиторы акт
BRPI1015983A2 (pt)	2016-04-19	composto, uso do composto, método para tratar um paciente, e, composição farmacêutica.
AR088297A1 (es)	2014-05-21	R(+)-n-formil-propargil-aminoindano
CL2014000393A1 (es)	2014-08-01	Compuestos derivados de benzofurano y sus sales, como inhibidores del virus de hepatitis c; composicion farmaceutica que los comprende; y su uso para el tratamiento o la prevencion de una infeccion por el virus de hepatitis c o de una enfermedad asociada con dicha infeccion.
CR20140380A (es)	2014-10-28	Inhibidores de pirazolopirimidinilo de enzima activadora de ubiquitina
PE20150167A1 (es)	2015-02-07	(r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
EA201171414A1 (ru)	2012-06-29	Ингибиторы белков семейства iap
EA201200485A1 (ru)	2012-10-30	Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол
CR20110542A (es)	2012-01-30	Compuestos y Métodos para Tratamiento Viral
CL2013002584A1 (es)	2014-02-21	Compuestos derivados de 2-(2-metilpropanoil)pirazolidin-3-carboxamida, inhibidores de la peptido desformilasa (pdf); composición farmaceutica, utiles en el tratamiento de una infeccion bacteriana.